Correlation Between ALPS Medical and Loncar Cancer

Can any of the company-specific risk be diversified away by investing in both ALPS Medical and Loncar Cancer at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ALPS Medical and Loncar Cancer into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ALPS Medical Breakthroughs and Loncar Cancer Immunotherapy, you can compare the effects of market volatilities on ALPS Medical and Loncar Cancer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ALPS Medical with a short position of Loncar Cancer. Check out your portfolio center. Please also check ongoing floating volatility patterns of ALPS Medical and Loncar Cancer.

Diversification Opportunities for ALPS Medical and Loncar Cancer

0.69

Correlation Coefficient

ALPS Medical  Loncar Cancer

Poor diversification

The 3 months correlation between ALPS and Loncar is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding ALPS Medical Breakthroughs and Loncar Cancer Immunotherapy in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Loncar Cancer Immuno and ALPS Medical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ALPS Medical Breakthroughs are associated (or correlated) with Loncar Cancer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Loncar Cancer Immuno has no effect on the direction of ALPS Medical i.e., ALPS Medical and Loncar Cancer go up and down completely randomly.

Pair Corralation between ALPS Medical and Loncar Cancer

Given the investment horizon of 90 days ALPS Medical Breakthroughs is expected to generate 0.94 times more return on investment than Loncar Cancer. However, ALPS Medical Breakthroughs is 1.07 times less risky than Loncar Cancer. It trades about -0.15 of its potential returns per unit of risk. Loncar Cancer Immunotherapy is currently generating about -0.24 per unit of risk. If you would invest  3,689  in ALPS Medical Breakthroughs on September 20, 2024 and sell it today you would lose (248.00) from holding ALPS Medical Breakthroughs or give up 6.72% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	95.45%
Values	Daily Returns

ALPS Medical Breakthroughs  vs.  Loncar Cancer Immunotherapy

ALPS Medical Breakth

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ALPS Medical Breakthroughs has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Loncar Cancer Immuno

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors.

Pair Trading with ALPS Medical and Loncar Cancer

The main advantage of trading using opposite ALPS Medical and Loncar Cancer positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ALPS Medical position performs unexpectedly, Loncar Cancer can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will offset losses from the drop in Loncar Cancer's long position.

The idea behind ALPS Medical Breakthroughs and Loncar Cancer Immunotherapy pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.